Cayman
Showing 43501–43650 of 45550 results
-
Ursodeoxycholic acid (UDCA) is a secondary bile acid formed via epimerization of chenodeoxycholic acid (CDCA; Item No. 10011286).{48224,48225} UDCA is also a metabolite of lithocholic acid (LCA; Item No. 20253) in human liver microsomes.{48226} It inhibits taurocholic acid (Item No. 16215) uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM.{24182} UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid (DCA; Item Nos. 20756 | 18231) or ethanol in primary rat hepatocytes.{48227} Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis. UDCA MaxSpec® standard is a quantitative grade standard of UDCA that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This UDCA MaxSpec® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.
Brand:CaymanSKU:31367 - 100 µgAvailable on backorder
Ursodeoxycholic acid-d4 (UDCA-d4) is intended for use as an internal standard for the quantification of UDCA (Item No. 15121) by GC- or LC-MS. UDCA is a secondary bile acid formed via epimerization of chenodeoxycholic acid (CDCA; Item No. 10011286).{48224,48225} UDCA is also a metabolite of lithocholic acid (LCA; Item No. 20253) in human liver microsomes.{48226} It inhibits taurocholic acid (Item No. 16215) uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM.{24182} UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid (DCA; Item Nos. 20756 | 18231) or ethanol in primary rat hepatocytes.{48227} Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis.
Brand:CaymanSKU:21892 -Out of stock
Ursodeoxycholic acid-d4 (UDCA-d4) is intended for use as an internal standard for the quantification of UDCA (Item No. 15121) by GC- or LC-MS. UDCA is a secondary bile acid formed via epimerization of chenodeoxycholic acid (CDCA; Item No. 10011286).{48224,48225} UDCA is also a metabolite of lithocholic acid (LCA; Item No. 20253) in human liver microsomes.{48226} It inhibits taurocholic acid (Item No. 16215) uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM.{24182} UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid (DCA; Item Nos. 20756 | 18231) or ethanol in primary rat hepatocytes.{48227} Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis.
Brand:CaymanSKU:21892 -Out of stock
Ursodeoxycholic acid-d4 (UDCA-d4) is intended for use as an internal standard for the quantification of UDCA (Item No. 15121) by GC- or LC-MS. UDCA is a secondary bile acid formed via epimerization of chenodeoxycholic acid (CDCA; Item No. 10011286).{48224,48225} UDCA is also a metabolite of lithocholic acid (LCA; Item No. 20253) in human liver microsomes.{48226} It inhibits taurocholic acid (Item No. 16215) uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM.{24182} UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid (DCA; Item Nos. 20756 | 18231) or ethanol in primary rat hepatocytes.{48227} Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis.
Brand:CaymanSKU:21892 -Out of stock
Ursodeoxycholic acid-d4 (UDCA-d4) is intended for use as an internal standard for the quantification of UDCA (Item No. 15121) by GC- or LC-MS. UDCA is a secondary bile acid formed via epimerization of chenodeoxycholic acid (CDCA; Item No. 10011286).{48224,48225} UDCA is also a metabolite of lithocholic acid (LCA; Item No. 20253) in human liver microsomes.{48226} It inhibits taurocholic acid (Item No. 16215) uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM.{24182} UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid (DCA; Item Nos. 20756 | 18231) or ethanol in primary rat hepatocytes.{48227} Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis. Ursodeoxycholic Acid-d4 MaxSpec® standard is a quantitative grade standard of Ursodeoxycholic Acid-d4 (Item No. 21892) that has been prepared specifically for mass spectrometry and related applications where quantitative reproducibility is required. The solution has been prepared gravimetrically and is supplied in a deactivated glass ampule sealed under argon. The concentration was verified by comparison to an independently prepared calibration standard. This Ursodeoxycholic Acid-d4 MaxSpec® standard is guaranteed to meet identity, purity, stability, and concentration specifications and is provided with a batch-specific certificate of analysis. Ongoing stability testing is performed to ensure the concentration remains accurate throughout the shelf life of the product. Note: The amount of solution added to the vial is in excess of the listed amount. Therefore, it is necessary to accurately measure volumes for preparation of calibration standards. Follow recommended storage and handling conditions to maintain product quality.
Brand:CaymanSKU:31368 - 100 µgAvailable on backorder
Ursolic acid is a pentacyclic triterpenoid that has been isolated from M. pumila and has diverse biological activities, including anticancer, hepatoprotective, anti-inflammatory, antioxidant, antimicrobial, and cardioprotective properties.{45002,15043,45003,45004} It inhibits the proliferation of HepG2 liver, MCF-7 breast, and Caco-2 colon cancer cells (EC50s = 87.4, 14.4, and 34.4 μM, respectively).{15043} Ursolic acid reverses increases in hepatic steatosis, levels of hepatic triglycerides and free fatty acids, and hepatic TNF-α, IL-1β, IL-6, and IL-8 mRNA expression in a dose-dependent manner in a high-fat diet-induced rat model of non-alcoholic fatty liver disease (NAFLD).{45004} Ursolic acid also scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals (IC50 = 59.7 μg/ml) and inhibits the growth of several strains of Gram-positive and Gram-negative bacteria in vitro including S. aureus, E. coli, P. aeruginosa, K. pneumoniae, and S. flexneri (MICs = 32-512 μg/ml).{45003}
Brand:CaymanSKU:10072 - 100 mgAvailable on backorder
Ursolic acid is a pentacyclic triterpenoid that has been isolated from M. pumila and has diverse biological activities, including anticancer, hepatoprotective, anti-inflammatory, antioxidant, antimicrobial, and cardioprotective properties.{45002,15043,45003,45004} It inhibits the proliferation of HepG2 liver, MCF-7 breast, and Caco-2 colon cancer cells (EC50s = 87.4, 14.4, and 34.4 μM, respectively).{15043} Ursolic acid reverses increases in hepatic steatosis, levels of hepatic triglycerides and free fatty acids, and hepatic TNF-α, IL-1β, IL-6, and IL-8 mRNA expression in a dose-dependent manner in a high-fat diet-induced rat model of non-alcoholic fatty liver disease (NAFLD).{45004} Ursolic acid also scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals (IC50 = 59.7 μg/ml) and inhibits the growth of several strains of Gram-positive and Gram-negative bacteria in vitro including S. aureus, E. coli, P. aeruginosa, K. pneumoniae, and S. flexneri (MICs = 32-512 μg/ml).{45003}
Brand:CaymanSKU:10072 - 250 mgAvailable on backorder
Ursolic acid is a pentacyclic triterpenoid that has been isolated from M. pumila and has diverse biological activities, including anticancer, hepatoprotective, anti-inflammatory, antioxidant, antimicrobial, and cardioprotective properties.{45002,15043,45003,45004} It inhibits the proliferation of HepG2 liver, MCF-7 breast, and Caco-2 colon cancer cells (EC50s = 87.4, 14.4, and 34.4 μM, respectively).{15043} Ursolic acid reverses increases in hepatic steatosis, levels of hepatic triglycerides and free fatty acids, and hepatic TNF-α, IL-1β, IL-6, and IL-8 mRNA expression in a dose-dependent manner in a high-fat diet-induced rat model of non-alcoholic fatty liver disease (NAFLD).{45004} Ursolic acid also scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals (IC50 = 59.7 μg/ml) and inhibits the growth of several strains of Gram-positive and Gram-negative bacteria in vitro including S. aureus, E. coli, P. aeruginosa, K. pneumoniae, and S. flexneri (MICs = 32-512 μg/ml).{45003}
Brand:CaymanSKU:10072 - 50 mgAvailable on backorder
Usnic acid is a lichen metabolite with antioxidant, anticancer, antifungal, antiprotozoal, and antimicrobial activities.{38108,38109,38110,38111,38112} Usnic acid (>50 mg/kg) reduces the number of indomethacin-induced gastric ulcers in rats through decreased lipid peroxidation and decreased myeloperoxidase activity.{38108} It is fungicidal against C. orthopsilosis and C. parapsilosis (IC80s = 7.8 and 15.6 μg/ml, respectively) and bactericidal against seven vancomycin-resistant E. faecalis strains (MIC = 125 μg/ml).{38109,38110} Usnic acid (25 mg/kg, injected intralesionally) reduces L. amazonensis parasite loads by 72.3% in footpads of infected mice.{38111} It also reduces growth of A2780, HeLa, MCF-7, SK-BR-3, HT-29, HCT116, HL-60, and Jurkat cancer cells in vitro (IC50s = 48.5-199 μM).{38112}
Brand:CaymanSKU:22585 -Out of stock
Usnic acid is a lichen metabolite with antioxidant, anticancer, antifungal, antiprotozoal, and antimicrobial activities.{38108,38109,38110,38111,38112} Usnic acid (>50 mg/kg) reduces the number of indomethacin-induced gastric ulcers in rats through decreased lipid peroxidation and decreased myeloperoxidase activity.{38108} It is fungicidal against C. orthopsilosis and C. parapsilosis (IC80s = 7.8 and 15.6 μg/ml, respectively) and bactericidal against seven vancomycin-resistant E. faecalis strains (MIC = 125 μg/ml).{38109,38110} Usnic acid (25 mg/kg, injected intralesionally) reduces L. amazonensis parasite loads by 72.3% in footpads of infected mice.{38111} It also reduces growth of A2780, HeLa, MCF-7, SK-BR-3, HT-29, HCT116, HL-60, and Jurkat cancer cells in vitro (IC50s = 48.5-199 μM).{38112}
Brand:CaymanSKU:22585 -Out of stock
Usnic acid is a lichen metabolite with antioxidant, anticancer, antifungal, antiprotozoal, and antimicrobial activities.{38108,38109,38110,38111,38112} Usnic acid (>50 mg/kg) reduces the number of indomethacin-induced gastric ulcers in rats through decreased lipid peroxidation and decreased myeloperoxidase activity.{38108} It is fungicidal against C. orthopsilosis and C. parapsilosis (IC80s = 7.8 and 15.6 μg/ml, respectively) and bactericidal against seven vancomycin-resistant E. faecalis strains (MIC = 125 μg/ml).{38109,38110} Usnic acid (25 mg/kg, injected intralesionally) reduces L. amazonensis parasite loads by 72.3% in footpads of infected mice.{38111} It also reduces growth of A2780, HeLa, MCF-7, SK-BR-3, HT-29, HCT116, HL-60, and Jurkat cancer cells in vitro (IC50s = 48.5-199 μM).{38112}
Brand:CaymanSKU:22585 -Out of stock
Usnic acid is a lichen metabolite with antioxidant, anticancer, antifungal, antiprotozoal, and antimicrobial activities.{38108,38109,38110,38111,38112} Usnic acid (>50 mg/kg) reduces the number of indomethacin-induced gastric ulcers in rats through decreased lipid peroxidation and decreased myeloperoxidase activity.{38108} It is fungicidal against C. orthopsilosis and C. parapsilosis (IC80s = 7.8 and 15.6 μg/ml, respectively) and bactericidal against seven vancomycin-resistant E. faecalis strains (MIC = 125 μg/ml).{38109,38110} Usnic acid (25 mg/kg, injected intralesionally) reduces L. amazonensis parasite loads by 72.3% in footpads of infected mice.{38111} It also reduces growth of A2780, HeLa, MCF-7, SK-BR-3, HT-29, HCT116, HL-60, and Jurkat cancer cells in vitro (IC50s = 48.5-199 μM).{38112}
Brand:CaymanSKU:22585 -Out of stock
USP7-USP47 inhibitor is a dual inhibitor of ubiquitin-specific protease 7 (USP7) and USP47 (IC50s = 0.42 and 1 μM, respectively).{24462} It is selective for USP7 and USP47 over USP2, USP5, USP8, USP21, USP28, caspase-3, and cathepsin B (IC50s = >31.6 μM). USP7-USP47 inhibitor inhibits the growth of HCT116 cells (EC50 = 7.6 μM).
Brand:CaymanSKU:25622 - 1 mgAvailable on backorder
USP7-USP47 inhibitor is a dual inhibitor of ubiquitin-specific protease 7 (USP7) and USP47 (IC50s = 0.42 and 1 μM, respectively).{24462} It is selective for USP7 and USP47 over USP2, USP5, USP8, USP21, USP28, caspase-3, and cathepsin B (IC50s = >31.6 μM). USP7-USP47 inhibitor inhibits the growth of HCT116 cells (EC50 = 7.6 μM).
Brand:CaymanSKU:25622 - 10 mgAvailable on backorder
USP7-USP47 inhibitor is a dual inhibitor of ubiquitin-specific protease 7 (USP7) and USP47 (IC50s = 0.42 and 1 μM, respectively).{24462} It is selective for USP7 and USP47 over USP2, USP5, USP8, USP21, USP28, caspase-3, and cathepsin B (IC50s = >31.6 μM). USP7-USP47 inhibitor inhibits the growth of HCT116 cells (EC50 = 7.6 μM).
Brand:CaymanSKU:25622 - 5 mgAvailable on backorder
The receptors for retinoids, RARs and RXRs, form heterodimers with many other family members in order to control various physiological and pathological processes, including cancer and metabolic diseases. UVI3003 is a full antagonist of RXR that demonstrates potent, nanomolar binding affinity.{28139} At 1 µM, UVI3003 does not affect the corepressor interaction capacity of the RARα subunit in the RAR-RXR heterodimer configuration.{28139} This compound can be used to isolate the contribution of RXR to the function of RXR heterodimers.{28139,28140}
Brand:CaymanSKU:- The receptors for retinoids, RARs and RXRs, form heterodimers with many other family members in order to control various physiological and pathological processes, including cancer and metabolic diseases. UVI3003 is a full antagonist of RXR that demonstrates potent, nanomolar binding affinity.{28139} At 1 µM, UVI3003 does not affect the corepressor interaction capacity of the RARα subunit in the RAR-RXR heterodimer configuration.{28139} This compound can be used to isolate the contribution of RXR to the function of RXR heterodimers.{28139,28140}
Brand:CaymanSKU:- The receptors for retinoids, RARs and RXRs, form heterodimers with many other family members in order to control various physiological and pathological processes, including cancer and metabolic diseases. UVI3003 is a full antagonist of RXR that demonstrates potent, nanomolar binding affinity.{28139} At 1 µM, UVI3003 does not affect the corepressor interaction capacity of the RARα subunit in the RAR-RXR heterodimer configuration.{28139} This compound can be used to isolate the contribution of RXR to the function of RXR heterodimers.{28139,28140}
Brand:CaymanSKU:-
V-9302 is an inhibitor of amino acid transporter 2 (ASCT2).{56045} It inhibits glutamine uptake with IC50 values of 9 and 9.6 µM for the rat and human transporters, respectively. V-9302 also inhibits glutamine uptake in HEK293 cells and reduces cell viability of a variety of cancer cell lines, including HCT116, HT-29, COLO 205, and RKO cells (EC50s = 8.9, 9.4, 14.5, and 8.3 µM, respectively).{56046} It reduces glutamine uptake into tumor tissue and prevents tumor growth in HCT116 and HT-29 mouse xenograft models expressing K-RasG13D and BRAFV600E mutations, respectively, when administered at a dose of 75 mg/kg per day for 21 days.
Brand:CaymanSKU:27688 - 1 mgAvailable on backorder
V-9302 is an inhibitor of amino acid transporter 2 (ASCT2).{56045} It inhibits glutamine uptake with IC50 values of 9 and 9.6 µM for the rat and human transporters, respectively. V-9302 also inhibits glutamine uptake in HEK293 cells and reduces cell viability of a variety of cancer cell lines, including HCT116, HT-29, COLO 205, and RKO cells (EC50s = 8.9, 9.4, 14.5, and 8.3 µM, respectively).{56046} It reduces glutamine uptake into tumor tissue and prevents tumor growth in HCT116 and HT-29 mouse xenograft models expressing K-RasG13D and BRAFV600E mutations, respectively, when administered at a dose of 75 mg/kg per day for 21 days.
Brand:CaymanSKU:27688 - 10 mgAvailable on backorder
V-9302 is an inhibitor of amino acid transporter 2 (ASCT2).{56045} It inhibits glutamine uptake with IC50 values of 9 and 9.6 µM for the rat and human transporters, respectively. V-9302 also inhibits glutamine uptake in HEK293 cells and reduces cell viability of a variety of cancer cell lines, including HCT116, HT-29, COLO 205, and RKO cells (EC50s = 8.9, 9.4, 14.5, and 8.3 µM, respectively).{56046} It reduces glutamine uptake into tumor tissue and prevents tumor growth in HCT116 and HT-29 mouse xenograft models expressing K-RasG13D and BRAFV600E mutations, respectively, when administered at a dose of 75 mg/kg per day for 21 days.
Brand:CaymanSKU:27688 - 25 mgAvailable on backorder
V-9302 is an inhibitor of amino acid transporter 2 (ASCT2).{56045} It inhibits glutamine uptake with IC50 values of 9 and 9.6 µM for the rat and human transporters, respectively. V-9302 also inhibits glutamine uptake in HEK293 cells and reduces cell viability of a variety of cancer cell lines, including HCT116, HT-29, COLO 205, and RKO cells (EC50s = 8.9, 9.4, 14.5, and 8.3 µM, respectively).{56046} It reduces glutamine uptake into tumor tissue and prevents tumor growth in HCT116 and HT-29 mouse xenograft models expressing K-RasG13D and BRAFV600E mutations, respectively, when administered at a dose of 75 mg/kg per day for 21 days.
Brand:CaymanSKU:27688 - 5 mgAvailable on backorder
V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.{5063}
Brand:CaymanSKU:82160 - 10 mgAvailable on backorder
V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.{5063}
Brand:CaymanSKU:82160 - 100 mgAvailable on backorder
V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.{5063}
Brand:CaymanSKU:82160 - 5 mgAvailable on backorder
V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.{5063}
Brand:CaymanSKU:82160 - 50 mgAvailable on backorder
Vaborbactam is an inhibitor of β-lactamases (Kis = 29-110 nM for class A and class C enzymes).{36683} It is selective for bacterial β-lactamases over a panel of mammalian serine proteases (IC50s = ≥1,000 μM). Vaborbactam potentiates the activity of biapenem against K. pneumonia expressing the β-lactamase KPC-2, reducing the MIC value for biapenem from 32 to 1 μg/ml when used at a concentration of 0.02 μg/ml. It also potentiates the activity of the carbapenem antibiotics biapenem, meropenem (Item No. 16068), ertapenem, and imipenem (Item No. 16039) against clinical isolates of E. coli, E. cloacae, K. oxytoca, and K. pneumoniae that produce serine β-lactamases (MICs = ≤0.06-4 and 4-64 μg/ml in the presence and absence of vaborbactam, respectively). In vivo, vaborbactam (50 mg/kg) reduces the number of colony forming units (CFUs) in the lung in a neutropenic mouse lung infection model when used in combination with biapenem or meropenem. Formulations containing vaborbactam in combination with meropenem have been used for the treatment of carbapenem-resistant Enterobacteriaceae infections.
Brand:CaymanSKU:23962 - 1 mgAvailable on backorder
Vaborbactam is an inhibitor of β-lactamases (Kis = 29-110 nM for class A and class C enzymes).{36683} It is selective for bacterial β-lactamases over a panel of mammalian serine proteases (IC50s = ≥1,000 μM). Vaborbactam potentiates the activity of biapenem against K. pneumonia expressing the β-lactamase KPC-2, reducing the MIC value for biapenem from 32 to 1 μg/ml when used at a concentration of 0.02 μg/ml. It also potentiates the activity of the carbapenem antibiotics biapenem, meropenem (Item No. 16068), ertapenem, and imipenem (Item No. 16039) against clinical isolates of E. coli, E. cloacae, K. oxytoca, and K. pneumoniae that produce serine β-lactamases (MICs = ≤0.06-4 and 4-64 μg/ml in the presence and absence of vaborbactam, respectively). In vivo, vaborbactam (50 mg/kg) reduces the number of colony forming units (CFUs) in the lung in a neutropenic mouse lung infection model when used in combination with biapenem or meropenem. Formulations containing vaborbactam in combination with meropenem have been used for the treatment of carbapenem-resistant Enterobacteriaceae infections.
Brand:CaymanSKU:23962 - 10 mgAvailable on backorder
Vaborbactam is an inhibitor of β-lactamases (Kis = 29-110 nM for class A and class C enzymes).{36683} It is selective for bacterial β-lactamases over a panel of mammalian serine proteases (IC50s = ≥1,000 μM). Vaborbactam potentiates the activity of biapenem against K. pneumonia expressing the β-lactamase KPC-2, reducing the MIC value for biapenem from 32 to 1 μg/ml when used at a concentration of 0.02 μg/ml. It also potentiates the activity of the carbapenem antibiotics biapenem, meropenem (Item No. 16068), ertapenem, and imipenem (Item No. 16039) against clinical isolates of E. coli, E. cloacae, K. oxytoca, and K. pneumoniae that produce serine β-lactamases (MICs = ≤0.06-4 and 4-64 μg/ml in the presence and absence of vaborbactam, respectively). In vivo, vaborbactam (50 mg/kg) reduces the number of colony forming units (CFUs) in the lung in a neutropenic mouse lung infection model when used in combination with biapenem or meropenem. Formulations containing vaborbactam in combination with meropenem have been used for the treatment of carbapenem-resistant Enterobacteriaceae infections.
Brand:CaymanSKU:23962 - 5 mgAvailable on backorder
Vacquinols are a new class of quinine-derivatives that stimulate death in glioblastoma cells by massive macropinocytotic vacuolization, ATP depletion, and cytoplasmic membrane rupture.{26440} A key effector of vacquinols is MAPK kinase 4 (MKK4).{26440} Vacquinol-1 is an activator of MKK4-dependent macropinocytotic cell death in glioblastoma cells.{26440} It induces ATP depletion in glioblastoma cells (IC50 = 3.14 µM at 1 day) without affecting fibroblasts, embryonic stem cells, or osteosarcoma cells.{26440} Vacquinol-1 is orally bioavailable with good brain penetrance and excellent pharmacokinetics.{26440} Oral administration of vacquinol-1 (20 mg/kg once daily for five days) substantially impairs the growth of engrafted glioblastoma cell tumors in mice and prolongs survival.{26440}
Brand:CaymanSKU:-Out of stock
Vacquinols are a new class of quinine-derivatives that stimulate death in glioblastoma cells by massive macropinocytotic vacuolization, ATP depletion, and cytoplasmic membrane rupture.{26440} A key effector of vacquinols is MAPK kinase 4 (MKK4).{26440} Vacquinol-1 is an activator of MKK4-dependent macropinocytotic cell death in glioblastoma cells.{26440} It induces ATP depletion in glioblastoma cells (IC50 = 3.14 µM at 1 day) without affecting fibroblasts, embryonic stem cells, or osteosarcoma cells.{26440} Vacquinol-1 is orally bioavailable with good brain penetrance and excellent pharmacokinetics.{26440} Oral administration of vacquinol-1 (20 mg/kg once daily for five days) substantially impairs the growth of engrafted glioblastoma cell tumors in mice and prolongs survival.{26440}
Brand:CaymanSKU:-Out of stock
Vacquinols are a new class of quinine-derivatives that stimulate death in glioblastoma cells by massive macropinocytotic vacuolization, ATP depletion, and cytoplasmic membrane rupture.{26440} A key effector of vacquinols is MAPK kinase 4 (MKK4).{26440} Vacquinol-1 is an activator of MKK4-dependent macropinocytotic cell death in glioblastoma cells.{26440} It induces ATP depletion in glioblastoma cells (IC50 = 3.14 µM at 1 day) without affecting fibroblasts, embryonic stem cells, or osteosarcoma cells.{26440} Vacquinol-1 is orally bioavailable with good brain penetrance and excellent pharmacokinetics.{26440} Oral administration of vacquinol-1 (20 mg/kg once daily for five days) substantially impairs the growth of engrafted glioblastoma cell tumors in mice and prolongs survival.{26440}
Brand:CaymanSKU:-Out of stock
Vacquinols are a new class of quinine-derivatives that stimulate death in glioblastoma cells by massive macropinocytotic vacuolization, ATP depletion, and cytoplasmic membrane rupture.{26440} A key effector of vacquinols is MAPK kinase 4 (MKK4).{26440} Vacquinol-1 is an activator of MKK4-dependent macropinocytotic cell death in glioblastoma cells.{26440} It induces ATP depletion in glioblastoma cells (IC50 = 3.14 µM at 1 day) without affecting fibroblasts, embryonic stem cells, or osteosarcoma cells.{26440} Vacquinol-1 is orally bioavailable with good brain penetrance and excellent pharmacokinetics.{26440} Oral administration of vacquinol-1 (20 mg/kg once daily for five days) substantially impairs the growth of engrafted glioblastoma cell tumors in mice and prolongs survival.{26440}
Brand:CaymanSKU:-Out of stock
Vacuolin-1 is a cell-permeable inhibitor of lysosomal exocytosis that prevents Ca2+-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal content.{32919} It does not affect other membrane-bound organelles (including enlargeosomal exocytosis), disturb the organization of the actin or tubulin cytoskeletal network, nor interfere with trafficking along the endocytic or secretory pathways.{32919}
Brand:CaymanSKU:20425 -Available on backorder
Vacuolin-1 is a cell-permeable inhibitor of lysosomal exocytosis that prevents Ca2+-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal content.{32919} It does not affect other membrane-bound organelles (including enlargeosomal exocytosis), disturb the organization of the actin or tubulin cytoskeletal network, nor interfere with trafficking along the endocytic or secretory pathways.{32919}
Brand:CaymanSKU:20425 -Available on backorder
Vacuolin-1 is a cell-permeable inhibitor of lysosomal exocytosis that prevents Ca2+-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal content.{32919} It does not affect other membrane-bound organelles (including enlargeosomal exocytosis), disturb the organization of the actin or tubulin cytoskeletal network, nor interfere with trafficking along the endocytic or secretory pathways.{32919}
Brand:CaymanSKU:20425 -Available on backorder
Vacuolin-1 is a cell-permeable inhibitor of lysosomal exocytosis that prevents Ca2+-dependent fusion of lysosomes with the plasma membrane and the release of lysosomal content.{32919} It does not affect other membrane-bound organelles (including enlargeosomal exocytosis), disturb the organization of the actin or tubulin cytoskeletal network, nor interfere with trafficking along the endocytic or secretory pathways.{32919}
Brand:CaymanSKU:20425 -Available on backorder
Vadadustat is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase 2 (PHD2) and PHD3 (IC50s = 1.1 and 0.39 μM, respectively).{51165} It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum.
Brand:CaymanSKU:- Vadadustat is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase 2 (PHD2) and PHD3 (IC50s = 1.1 and 0.39 μM, respectively).{51165} It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum.
Brand:CaymanSKU:- Vadadustat is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase 2 (PHD2) and PHD3 (IC50s = 1.1 and 0.39 μM, respectively).{51165} It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum.
Brand:CaymanSKU:- Vadadustat is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase 2 (PHD2) and PHD3 (IC50s = 1.1 and 0.39 μM, respectively).{51165} It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum.
Brand:CaymanSKU:-
Valbenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2; Kis = 110 and 150 nM in rat striatum homogenates and human platelets, respectively).{47247} It is selective for VMAT2 over a panel of 80 receptors, transporters, and ion channels, including the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, and 5-HT2B and dopamine D1 and D2 receptors. Valbenazine induces ptosis in rats, indicating norepinephrine depletion. Formulations containing valbenazine have been used in the treatment of tardive dyskinesia.
Brand:CaymanSKU:26809 - 10 mgAvailable on backorder
Valbenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2; Kis = 110 and 150 nM in rat striatum homogenates and human platelets, respectively).{47247} It is selective for VMAT2 over a panel of 80 receptors, transporters, and ion channels, including the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, and 5-HT2B and dopamine D1 and D2 receptors. Valbenazine induces ptosis in rats, indicating norepinephrine depletion. Formulations containing valbenazine have been used in the treatment of tardive dyskinesia.
Brand:CaymanSKU:26809 - 25 mgAvailable on backorder
Valbenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2; Kis = 110 and 150 nM in rat striatum homogenates and human platelets, respectively).{47247} It is selective for VMAT2 over a panel of 80 receptors, transporters, and ion channels, including the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, and 5-HT2B and dopamine D1 and D2 receptors. Valbenazine induces ptosis in rats, indicating norepinephrine depletion. Formulations containing valbenazine have been used in the treatment of tardive dyskinesia.
Brand:CaymanSKU:26809 - 5 mgAvailable on backorder
Valbenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2; Kis = 110 and 150 nM in rat striatum homogenates and human platelets, respectively).{47247} It is selective for VMAT2 over a panel of 80 receptors, transporters, and ion channels, including the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, and 5-HT2B and dopamine D1 and D2 receptors. Valbenazine induces ptosis in rats, indicating norepinephrine depletion. Formulations containing valbenazine have been used in the treatment of tardive dyskinesia.
Brand:CaymanSKU:26809 - 50 mgAvailable on backorder
Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM for human recombinant COX-2 and COX-1, respectively).{42951} It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
Brand:CaymanSKU:10006120 - 10 mgAvailable on backorder
Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM for human recombinant COX-2 and COX-1, respectively).{42951} It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
Brand:CaymanSKU:10006120 - 25 mgAvailable on backorder
Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM for human recombinant COX-2 and COX-1, respectively).{42951} It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
Brand:CaymanSKU:10006120 - 5 mgAvailable on backorder
Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM for human recombinant COX-2 and COX-1, respectively).{42951} It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
Brand:CaymanSKU:10006120 - 50 mgAvailable on backorder
Valdecoxib-d3 is intended for use as an internal standard for the quantification of valdecoxib (Item No. 10006120) by GC- or LC-MS. Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM, for human recombinant COX-2 and COX-1, respectively).{42951} It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
Brand:CaymanSKU:28699 - 1 mgAvailable on backorder
Valdecoxib-d3 is intended for use as an internal standard for the quantification of valdecoxib (Item No. 10006120) by GC- or LC-MS. Valdecoxib is a selective inhibitor of COX-2 (IC50s = 0.005 and 140 µM, for human recombinant COX-2 and COX-1, respectively).{42951} It decreases LPS-induced production of prostaglandin E2 (PGE2; Item No. 14010) in isolated human whole blood (IC50 = 0.89 µM). Valdecoxib reduces carrageenan-induced paw edema and adjuvant-induced arthritis in rats (ED50s = 10.2 and 0.032 mg/kg, respectively).
Brand:CaymanSKU:28699 - 5 mgAvailable on backorder
Valemetostat is a dual inhibitor of enhancer of zeste homolog 1 (EZH1) and EZH2.{58162} It inhibits polycomb repressive complex 2 (PRC2) containing EZH1 or EZH2 as the catalytic subunit in cell-free assays (IC50s = 8.4 and 2.5 nM, respectively). Valemetostat inhibits trimethylation of histone H3 lysine 27 in HCT116 cells (IC50 = 0.44 nM). It inhibits the growth of Karpas-422 diffuse large B cell lymphoma (DLBCL) cells (GI50 = 4.8 nM).
Brand:CaymanSKU:31674 - 1 mgAvailable on backorder
Valemetostat is a dual inhibitor of enhancer of zeste homolog 1 (EZH1) and EZH2.{58162} It inhibits polycomb repressive complex 2 (PRC2) containing EZH1 or EZH2 as the catalytic subunit in cell-free assays (IC50s = 8.4 and 2.5 nM, respectively). Valemetostat inhibits trimethylation of histone H3 lysine 27 in HCT116 cells (IC50 = 0.44 nM). It inhibits the growth of Karpas-422 diffuse large B cell lymphoma (DLBCL) cells (GI50 = 4.8 nM).
Brand:CaymanSKU:31674 - 10 mgAvailable on backorder
Valemetostat is a dual inhibitor of enhancer of zeste homolog 1 (EZH1) and EZH2.{58162} It inhibits polycomb repressive complex 2 (PRC2) containing EZH1 or EZH2 as the catalytic subunit in cell-free assays (IC50s = 8.4 and 2.5 nM, respectively). Valemetostat inhibits trimethylation of histone H3 lysine 27 in HCT116 cells (IC50 = 0.44 nM). It inhibits the growth of Karpas-422 diffuse large B cell lymphoma (DLBCL) cells (GI50 = 4.8 nM).
Brand:CaymanSKU:31674 - 5 mgAvailable on backorder
Valemetostat is a dual inhibitor of enhancer of zeste homolog 1 (EZH1) and EZH2.{58162} It inhibits polycomb repressive complex 2 (PRC2) containing EZH1 or EZH2 as the catalytic subunit in cell-free assays (IC50s = 8.4 and 2.5 nM, respectively). Valemetostat inhibits trimethylation of histone H3 lysine 27 in HCT116 cells (IC50 = 0.44 nM). It inhibits the growth of Karpas-422 diffuse large B cell lymphoma (DLBCL) cells (GI50 = 4.8 nM).
Brand:CaymanSKU:31674 - 500 µgAvailable on backorder
Valeroyl salicylate is a selective, irreversible inhibitor of cyclooxygenase-1 (COX-1). The IC50 values for ovine COX-1 and -2 are 0.8 and 15 mM, respectively.{1364} The half-lives for inactivation of human recombinant and ovine COX-1 in the presence of 500 µM valeroyl salicylate are 12 and 45 minutes, respectively.{1284,1364}
Brand:CaymanSKU:70670 - 1 gAvailable on backorder
Valeroyl salicylate is a selective, irreversible inhibitor of cyclooxygenase-1 (COX-1). The IC50 values for ovine COX-1 and -2 are 0.8 and 15 mM, respectively.{1364} The half-lives for inactivation of human recombinant and ovine COX-1 in the presence of 500 µM valeroyl salicylate are 12 and 45 minutes, respectively.{1284,1364}
Brand:CaymanSKU:70670 - 100 mgAvailable on backorder
Valeroyl salicylate is a selective, irreversible inhibitor of cyclooxygenase-1 (COX-1). The IC50 values for ovine COX-1 and -2 are 0.8 and 15 mM, respectively.{1364} The half-lives for inactivation of human recombinant and ovine COX-1 in the presence of 500 µM valeroyl salicylate are 12 and 45 minutes, respectively.{1284,1364}
Brand:CaymanSKU:70670 - 50 mgAvailable on backorder
Valeroyl salicylate is a selective, irreversible inhibitor of cyclooxygenase-1 (COX-1). The IC50 values for ovine COX-1 and -2 are 0.8 and 15 mM, respectively.{1364} The half-lives for inactivation of human recombinant and ovine COX-1 in the presence of 500 µM valeroyl salicylate are 12 and 45 minutes, respectively.{1284,1364}
Brand:CaymanSKU:70670 - 500 mgAvailable on backorder
Valeryl-L-carnitine is a short-chain acylcarnitine and a derivative of L-carnitine (Item No. 21489). Valeryl-L-carnitine levels increase in the serum of rhesus monkeys following exposure to 7 and 10 Gray units (Gy) of ionizing radiation.{46127}
Brand:CaymanSKU:26563 - 10 mgAvailable on backorder
Valeryl-L-carnitine is a short-chain acylcarnitine and a derivative of L-carnitine (Item No. 21489). Valeryl-L-carnitine levels increase in the serum of rhesus monkeys following exposure to 7 and 10 Gray units (Gy) of ionizing radiation.{46127}
Brand:CaymanSKU:26563 - 25 mgAvailable on backorder
Valeryl-L-carnitine is a short-chain acylcarnitine and a derivative of L-carnitine (Item No. 21489). Valeryl-L-carnitine levels increase in the serum of rhesus monkeys following exposure to 7 and 10 Gray units (Gy) of ionizing radiation.{46127}
Brand:CaymanSKU:26563 - 5 mgAvailable on backorder
Valeryl-L-carnitine is a short-chain acylcarnitine and a derivative of L-carnitine (Item No. 21489). Valeryl-L-carnitine levels increase in the serum of rhesus monkeys following exposure to 7 and 10 Gray units (Gy) of ionizing radiation.{46127}
Brand:CaymanSKU:26563 - 50 mgAvailable on backorder
Valganciclovir is a valyl ester prodrug form of the antiviral nucleoside analog ganciclovir (Item No. 13853). In vivo, valganciclovir (200 mg/kg) increases survival and reduces weight loss in an immunosuppressed hamster model of disseminated adenovirus type 5 (Ad5) infection.{52613} Formulations containing valganciclovir have been used in the prevention of post-transplant cytomegalovirus (CMV) infections.
Brand:CaymanSKU:- Valganciclovir is a valyl ester prodrug form of the antiviral nucleoside analog ganciclovir (Item No. 13853). In vivo, valganciclovir (200 mg/kg) increases survival and reduces weight loss in an immunosuppressed hamster model of disseminated adenovirus type 5 (Ad5) infection.{52613} Formulations containing valganciclovir have been used in the prevention of post-transplant cytomegalovirus (CMV) infections.
Brand:CaymanSKU:- Valganciclovir is a valyl ester prodrug form of the antiviral nucleoside analog ganciclovir (Item No. 13853). In vivo, valganciclovir (200 mg/kg) increases survival and reduces weight loss in an immunosuppressed hamster model of disseminated adenovirus type 5 (Ad5) infection.{52613} Formulations containing valganciclovir have been used in the prevention of post-transplant cytomegalovirus (CMV) infections.
Brand:CaymanSKU:- Valganciclovir is a valyl ester prodrug form of the antiviral nucleoside analog ganciclovir (Item No. 13853). In vivo, valganciclovir (200 mg/kg) increases survival and reduces weight loss in an immunosuppressed hamster model of disseminated adenovirus type 5 (Ad5) infection.{52613} Formulations containing valganciclovir have been used in the prevention of post-transplant cytomegalovirus (CMV) infections.
Brand:CaymanSKU:-
Validamycin A is an antifungal agent used to protect rice plants against sheath blight caused by the pathogenic fungus, R. solani, due to its ability to inhibit trehalase, a trehalose-hydrolizing enzyme (Ki = 1.9 nM; IC50 = 0.7 μM).{24963} It is also effective against the growth and sporulation of R. cerealis, F. culmorum, and other fungi.{24962} This compound has also been used to study trehalase activity and trehalose biosynthesis.{24961}
Brand:CaymanSKU:- Validamycin A is an antifungal agent used to protect rice plants against sheath blight caused by the pathogenic fungus, R. solani, due to its ability to inhibit trehalase, a trehalose-hydrolizing enzyme (Ki = 1.9 nM; IC50 = 0.7 μM).{24963} It is also effective against the growth and sporulation of R. cerealis, F. culmorum, and other fungi.{24962} This compound has also been used to study trehalase activity and trehalose biosynthesis.{24961}
Brand:CaymanSKU:- Validamycin A is an antifungal agent used to protect rice plants against sheath blight caused by the pathogenic fungus, R. solani, due to its ability to inhibit trehalase, a trehalose-hydrolizing enzyme (Ki = 1.9 nM; IC50 = 0.7 μM).{24963} It is also effective against the growth and sporulation of R. cerealis, F. culmorum, and other fungi.{24962} This compound has also been used to study trehalase activity and trehalose biosynthesis.{24961}
Brand:CaymanSKU:-
Valilactone is an esterase inhibitor produced by a cultured strain of soil actinomycetes.{32633} It is reported to inhibit hog liver esterase and hog pancreas lipase with IC50 values of 29 and 0.14 ng/ml, respectively.{32633} Valilactone can also inhibit fatty acid synthase with an IC50 value of 0.30 µM and demonstrates selective toxicity towards MDA-MB-231 breast cancer cells with an IC50 value of 10.5 µM.{17922}
Brand:CaymanSKU:- Valilactone is an esterase inhibitor produced by a cultured strain of soil actinomycetes.{32633} It is reported to inhibit hog liver esterase and hog pancreas lipase with IC50 values of 29 and 0.14 ng/ml, respectively.{32633} Valilactone can also inhibit fatty acid synthase with an IC50 value of 0.30 µM and demonstrates selective toxicity towards MDA-MB-231 breast cancer cells with an IC50 value of 10.5 µM.{17922}
Brand:CaymanSKU:- Valilactone is an esterase inhibitor produced by a cultured strain of soil actinomycetes.{32633} It is reported to inhibit hog liver esterase and hog pancreas lipase with IC50 values of 29 and 0.14 ng/ml, respectively.{32633} Valilactone can also inhibit fatty acid synthase with an IC50 value of 0.30 µM and demonstrates selective toxicity towards MDA-MB-231 breast cancer cells with an IC50 value of 10.5 µM.{17922}
Brand:CaymanSKU:- Valilactone is an esterase inhibitor produced by a cultured strain of soil actinomycetes.{32633} It is reported to inhibit hog liver esterase and hog pancreas lipase with IC50 values of 29 and 0.14 ng/ml, respectively.{32633} Valilactone can also inhibit fatty acid synthase with an IC50 value of 0.30 µM and demonstrates selective toxicity towards MDA-MB-231 breast cancer cells with an IC50 value of 10.5 µM.{17922}
Brand:CaymanSKU:-
Valinomycin is a cyclododecadepsipeptide potassium-selective ionophore antibiotic that is isolated from various strains of Streptomyces. The hydrophilic interior is the right size to accommodate the potassium ion, but not other ions, while the hydrophobic exterior allows the complex to pass through the lipid bilayer. Valinomycin induces apoptosis in several cell types, including CHO cells, by stimulating potassium efflux. Apoptotic events produced by valinomycin include phosphatidylserine membrane translocation, caspase-3 activation, and mitochondrial membrane depolarization. {14421} Due to the ion-selective nature of valinomycin, it is used in ion-selective electrodes.
Brand:CaymanSKU:10009152 - 10 mgAvailable on backorder
Valinomycin is a cyclododecadepsipeptide potassium-selective ionophore antibiotic that is isolated from various strains of Streptomyces. The hydrophilic interior is the right size to accommodate the potassium ion, but not other ions, while the hydrophobic exterior allows the complex to pass through the lipid bilayer. Valinomycin induces apoptosis in several cell types, including CHO cells, by stimulating potassium efflux. Apoptotic events produced by valinomycin include phosphatidylserine membrane translocation, caspase-3 activation, and mitochondrial membrane depolarization. {14421} Due to the ion-selective nature of valinomycin, it is used in ion-selective electrodes.
Brand:CaymanSKU:10009152 - 25 mgAvailable on backorder
Valinomycin is a cyclododecadepsipeptide potassium-selective ionophore antibiotic that is isolated from various strains of Streptomyces. The hydrophilic interior is the right size to accommodate the potassium ion, but not other ions, while the hydrophobic exterior allows the complex to pass through the lipid bilayer. Valinomycin induces apoptosis in several cell types, including CHO cells, by stimulating potassium efflux. Apoptotic events produced by valinomycin include phosphatidylserine membrane translocation, caspase-3 activation, and mitochondrial membrane depolarization. {14421} Due to the ion-selective nature of valinomycin, it is used in ion-selective electrodes.
Brand:CaymanSKU:10009152 - 5 mgAvailable on backorder
Valinomycin is a cyclododecadepsipeptide potassium-selective ionophore antibiotic that is isolated from various strains of Streptomyces. The hydrophilic interior is the right size to accommodate the potassium ion, but not other ions, while the hydrophobic exterior allows the complex to pass through the lipid bilayer. Valinomycin induces apoptosis in several cell types, including CHO cells, by stimulating potassium efflux. Apoptotic events produced by valinomycin include phosphatidylserine membrane translocation, caspase-3 activation, and mitochondrial membrane depolarization. {14421} Due to the ion-selective nature of valinomycin, it is used in ion-selective electrodes.
Brand:CaymanSKU:10009152 - 50 mgAvailable on backorder
Valnoctamide is an isomer of the valproic acid amide, valpromide. It has been marketed as an anxiolytic and sedative compound and suppresses neuropathic pain.{29670,29672} Unlike valpromide, valnoctamide is not metabolized to its acid form, valnoctic acid, in vivo and has no teratogenicity.{29670} It abolishes the activity of myo-inositol-1-phosphate synthase in human brain crude homogenates (Ki = 0.18 mM).{21734} Valnoctamide suppresses electrographic seizures in animal models of status epilepticus, suggesting potential applications in managing epilepsy.{29671}
Brand:CaymanSKU:-Available on backorder
Valnoctamide is an isomer of the valproic acid amide, valpromide. It has been marketed as an anxiolytic and sedative compound and suppresses neuropathic pain.{29670,29672} Unlike valpromide, valnoctamide is not metabolized to its acid form, valnoctic acid, in vivo and has no teratogenicity.{29670} It abolishes the activity of myo-inositol-1-phosphate synthase in human brain crude homogenates (Ki = 0.18 mM).{21734} Valnoctamide suppresses electrographic seizures in animal models of status epilepticus, suggesting potential applications in managing epilepsy.{29671}
Brand:CaymanSKU:-Available on backorder
Valnoctamide is an isomer of the valproic acid amide, valpromide. It has been marketed as an anxiolytic and sedative compound and suppresses neuropathic pain.{29670,29672} Unlike valpromide, valnoctamide is not metabolized to its acid form, valnoctic acid, in vivo and has no teratogenicity.{29670} It abolishes the activity of myo-inositol-1-phosphate synthase in human brain crude homogenates (Ki = 0.18 mM).{21734} Valnoctamide suppresses electrographic seizures in animal models of status epilepticus, suggesting potential applications in managing epilepsy.{29671}
Brand:CaymanSKU:-Available on backorder